ArticleJAMA oncology2026
Trends in Meningioma Incidence, Treatment, and Imaging Surveillance.
Article in JAMA oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Meningioma incidence is rising globally, yet many tumors follow an indolent course. Despite low intervention rates, surveillance imaging is extensive, and it is unclear whether current practices meaningfully influence treatment decisions. Objective: To quantify nationwide Danish trends in meningioma incidence, treatment, and surveillance and identify potentially redundant follow-up imaging. Design, Setting, and Participants: This nationwide quality improvement study integrated data from the Danish National Patient Registry and Danish Pathology Registry. All adults diagnosed with meningioma based on radiologic or histopathologic findings in Denmark between January 1, 2010, and December 31, 2023, were included. Follow-up extended through December 31, 2024. Exposure: Meningioma diagnosis and neuroimaging. Main Outcomes and Measures: The primary outcomes were trends in meningioma incidence from 2010 through 2023, treatment conversion rates (surgery or radiotherapy), and surveillance imaging volume. Secondary outcomes included intervention timing and imaging use after final treatment. Results: A total of 8134 patients with meningioma were included (median age, 66 years [range, 18-102 years]; 6002 [73.7%] women). The age- and sex-standardized incidence rate increased from 6.4 (95% CI, 5.0-7.8) to 12.6 (95% CI, 10.8-14.5) per 100 000 person-years between 2010 and 2023, yet yearly treatment rates remained stable. A total of 5307 patients (65.2%) received no treatment, while 2665 (32.8%) underwent surgery and 439 (5.4%) received radiotherapy. Histopathologic examination confirmed World Health Organization grade 1 tumors in 2379 patients who underwent surgery (89.3%). Surveillance imaging was common, with 7143 patients (87.8%) receiving 1 or more follow-up magnetic resonance imaging (MRI) scan. Of 28 736 MRI scans, 23 992 (83.5%) were not followed by treatment. Imaging beyond 5 years after diagnosis rarely led to changes in treatment but accounted for a substantial proportion of total scans. Only 78 of 5547 patients (1.4%) underwent surgery after year 5. Conclusions and Relevance: In this quality improvement study, meningioma incidence increased substantially between 2010 and 2023, while treatment rates remained stable. Most imaging did not result in intervention, suggesting that a substantial proportion of follow-up imaging could be reduced within a risk-adapted framework.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.